Illumina (NASDAQ:ILMN) PT Raised to $126.00

Illumina (NASDAQ:ILMN) had its price objective boosted by TD Cowen from $122.00 to $126.00 in a report released on Wednesday, Benzinga reports. They currently have a hold rating on the life sciences company’s stock.

Several other equities analysts have also recently weighed in on the company. JPMorgan Chase & Co. cut their price objective on Illumina from $130.00 to $125.00 and set a neutral rating for the company in a research report on Wednesday. Scotiabank lowered their price target on Illumina from $185.00 to $176.00 and set a sector outperform rating on the stock in a research note on Monday, May 6th. Robert W. Baird boosted their price target on Illumina from $119.00 to $124.00 and gave the company a neutral rating in a research note on Wednesday. Jefferies Financial Group started coverage on Illumina in a research note on Monday, June 3rd. They set a hold rating and a $115.00 price target on the stock. Finally, Stephens restated an overweight rating and set a $170.00 price target on shares of Illumina in a research note on Wednesday, July 10th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of Hold and a consensus target price of $149.15.

Illumina Stock Performance

Shares of NASDAQ ILMN traded down $3.14 during trading hours on Wednesday, hitting $123.56. 1,860,377 shares of the company’s stock were exchanged, compared to its average volume of 2,122,721. Illumina has a 1-year low of $89.00 and a 1-year high of $195.64. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.75 and a quick ratio of 1.36. The stock has a market capitalization of $19.68 billion, a price-to-earnings ratio of -15.16 and a beta of 1.15. The company’s 50-day moving average price is $112.98 and its 200-day moving average price is $123.03.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.24. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The business had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same quarter in the previous year, the firm earned $0.32 EPS. The firm’s revenue was down 5.4% compared to the same quarter last year. On average, sell-side analysts expect that Illumina will post 1.5 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ILMN. Raymond James Financial Services Advisors Inc. lifted its holdings in Illumina by 22.6% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 8,576 shares of the life sciences company’s stock worth $1,194,000 after buying an additional 1,582 shares in the last quarter. Private Trust Co. NA lifted its holdings in Illumina by 42.9% during the 4th quarter. Private Trust Co. NA now owns 756 shares of the life sciences company’s stock worth $105,000 after buying an additional 227 shares in the last quarter. International Assets Investment Management LLC lifted its holdings in Illumina by 210.5% during the 4th quarter. International Assets Investment Management LLC now owns 48,194 shares of the life sciences company’s stock worth $6,711,000 after buying an additional 32,672 shares in the last quarter. Nisa Investment Advisors LLC lifted its holdings in Illumina by 238.1% during the 4th quarter. Nisa Investment Advisors LLC now owns 31,844 shares of the life sciences company’s stock worth $4,434,000 after buying an additional 22,425 shares in the last quarter. Finally, RFG Advisory LLC lifted its holdings in Illumina by 41.0% during the 4th quarter. RFG Advisory LLC now owns 3,267 shares of the life sciences company’s stock worth $455,000 after buying an additional 950 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.